Ausgabe 11/2016
Inhalt (11 Artikel)
From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare
Matthijs Versteegh, Saskia Knies, Werner Brouwer
Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation
Padraig Dixon, George Davey Smith, Stephanie von Hinke, Neil M. Davies, William Hollingworth
Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies
Feng Xie, Bruno Kovic, Xuejing Jin, Xiaoning He, Mengxiao Wang, Camila Silvestre
The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence
Eleftherios Sideris, Mark Corbett, Stephen Palmer, Nerys Woolacott, Laura Bojke
A Methodological Review of US Budget-Impact Models for New Drugs
Josephine Mauskopf, Stephanie Earnshaw
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
Matthijs Versteegh
Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK
Jamie Elvidge, Ash Bullement, Anthony J. Hatswell
Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations
Cynthia P. Iglesias, Alexander Thompson, Wolf H. Rogowski, Katherine Payne
Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience
François Bocquet, Anaïs Loubière, Isabelle Fusier, Anne-Laure Cordonnier, Pascal Paubel
Discretely Integrated Condition Event Simulation for Pharmacoeconomics
Mondher Toumi, Ekkehard Beck, Steve Sherman, Leyla Mohseninejad, Samuel Aballéa
Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics
J. Jaime Caro